Mary Yackey, OD
Optometrist · Cincinnati, OHNPI 1386694461
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 62.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $52,233, more than ten times the $774 reported in 2019. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $420.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$76K
- Apellis Pharmaceuticals, Inc.$23K
- Notal Vision, Inc.$8K
- Topcon Healthcare, Inc.$5K
- Bausch & Lomb Americas Inc.$2K
- Tarsus Pharmaceuticals, Inc.$2K
- plus $6K from 25 others
Across 68 payments — averaging $39.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$3K
What the payments were for
- Consulting fees$36,25730%
- Speaking & faculty fees$52,86043%
- Travel & lodging$22,52118%
- Food & beverage$10,3018%
- Gifts$320%
- Entertainment$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 103 | $75,643 |
| Apellis Pharmaceuticals, Inc. | 45 | $23,060 |
| Notal Vision, Inc. | 9 | $8,116 |
| Topcon Healthcare, Inc. | 5 | $5,432 |
| Bausch & Lomb Americas Inc. | 10 | $2,334 |
| Tarsus Pharmaceuticals, Inc. | 19 | $1,790 |
| Haag-streit USA, Inc. | 9 | $1,294 |
| Glaukos Corporation | 2 | $597 |
| Regeneron Healthcare Solutions, Inc. | 13 | $533 |
| Carl Zeiss Meditec USA, Inc. | 8 | $491 |
| Alimera Sciences, Inc. | 23 | $470 |
| LKC Technologies, Inc. | 1 | $450 |
| Alcon | 3 | $309 |
| Coopervision Inc. | 2 | $226 |
| Genentech USA, Inc. | 7 | $161 |
| ANI Pharmaceuticals, Inc. | 10 | $159 |
| Aerie Pharmaceuticals, Inc. | 3 | $147 |
| Astellas US LLC | 1 | $136 |
| Johnson & Johnson Vision Care, Inc. | 1 | $127 |
| Kala Pharmaceuticals, Inc. | 1 | $122 |
| Astellas Pharma Global Development | 1 | $100 |
| AbbVie | 3 | $62 |
| Optos, Inc. | 1 | $57 |
| Harrow Eye, LLC | 1 | $42 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $41 |
| Lombart Brothers, Inc. | 2 | $36 |
| Dompe US, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Eyepoint US, Inc. | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$61,429
- Syfovre$20,460
- Foresee Home$7,040
- KXL System$563
- CIRRUS HD-OCT$413
- XDEMVY$361
- ForeseeHome$324
- MiSight Contact Lens$226
- Hydrus Microstent$135
- EYLEA$134
- Acuvue$127
- EYSUVIS$122
- EYLEA HD$117
- Rhopressa$117
- Rocklatan$117
- XIIDRA$110
- MIEBO$110
- TRYPTYR$106
- INFUSE$104
How this compares
$122,027 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 94 | $177,365 |
| RestasisCyclosporine | 23 | $38,384 |
| Prednisolone Acetate | 157 | $5,536 |
| Difluprednate | 22 | $2,160 |
| ErythromycinErythromycin Base | 211 | $1,872 |
| Doxycycline Hyclate | 20 | $1,050 |
| Brimonidine Tartrate | 36 | $1,037 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $465 |
| Ketorolac Tromethamine | 35 | $462 |
| Latanoprost | 43 | $270 |
| Timolol Maleate | 37 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,790 | $177,36594 claims |
| AbbVieRestasis | $62 | $38,38423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Cincinnati
- Carly RoseCincinnati$203K
- John LahrCincinnati$145K
- Elliot KirsteinCincinnati$18K
- Todd ZelczakCincinnati$15K
- Rawzi BaikCincinnati$14K
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Thomas ChesterCleveland$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.